Page 686«..1020..685686687688..700710..»

Major Effects Drinking Wine Has on Your Health, Says Science | Eat This Not That – Eat This, Not That

Posted: August 5, 2021 at 1:59 am

Whether you love drinking a glass of chardonnay with your midday meal or can't make your famous pasta sauce without adding a pour of pinot, countless people consider wine an essential component of many a meal. However, while you may imagine you're sipping your way to better health with every glass, the benefits you reap from your wine intake have a lot to do with how much you consume, your biology, and other possible risk factors you may not even realize.

Before you pour another glass, read on to discover the major effects drinking wine has on your health, according to science. And for some dietary additions virtually everyone could benefit from, check out The 7 Healthiest Foods to Eat Right Now.

While many people know that alcoholic beverages like wine can have an effect on their liver health, it's not as commonly known that those drinks can have a profound effect on a person's risk of cancer north of the neck, too.

In fact, a 2004 study published in Oral Oncology found that, similar to other alcoholic beverages, wine was associated with an increased risk of both oral cancer and cancer of the pharynx, with risk increasing along with total alcohol consumption.

Want to better protect your health? Start by ditching the 50 Worst Foods to Never Eat if Cancer Runs in Your Family.

If you want to reduce your lifetime cancer risk, you may want to scale back your wine consumption starting now.

According to a 2019 research article published in BMC Public Health, drinking a bottle of wine a week increases a person's lifetime cancer risk as much as smoking five cigarettes for men and 10 cigarettes for women.

RELATED: For the latest healthy eating news delivered to your inbox, sign up for our newsletter!

While alcohol has a reputation for being harmful to your liver, wine may have less of a detrimental effect on this vital organ than other types of boozein fact, it may actually have a protective effect.

According to a 2018 study published in The American Journal of Gastroenterology, among patients with non-alcoholic fatty liver disease, those who drank wine in a non-binge-type fashion were less likely to have liver scarring than those who drank other types of alcohol or no alcohol.

READ MORE: Drinking Habits That May Cause Liver Damage, According to Science

You've likely heard that wine is good for your heart, and research suggests that's truewhen consumed in moderation, at least.

A 2001 study published in the International Journal of Molecular Medicine found that the polyphenol resveratrol in red wine may help protect against heart disease. However, other studies have found that high rates of alcohol consumptionbut not specifically wine consumptioncan increase a person's risk of various types of cardiovascular disease, so it's important to keep those drinks to a minimum.

For more ways to protect your cardiovascular health, start by cutting The 50 Foods That Have Been Linked to Heart Disease.

If you want to keep those pearly whites healthy, making wine part of your regular routine is a good place to start. A 2018 study published in the Journal of Agricultural Food Chemistry found that the caffeic and p-coumaric acids found in red wine made it more difficult for the bacteria that form dental plaque and cavities to adhere to teeth and gums, lessening the likelihood that they will cause decay and disease over time.

Read this next:

Excerpt from:
Major Effects Drinking Wine Has on Your Health, Says Science | Eat This Not That - Eat This, Not That

Posted in Molecular Medicine | Comments Off on Major Effects Drinking Wine Has on Your Health, Says Science | Eat This Not That – Eat This, Not That

Mel-Mont Medical announces the validation of its patented self-sampling technology, Ma by XytoTest, for molecular screening using HPV-DNA and 7-Type…

Posted: August 5, 2021 at 1:59 am

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest, receives clinical validation as being equally effective to clinician-collected sampling.

"Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease. Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.

The Mia by XytoTest device can be safely used by women at home, or in-office by a clinician, without the need for a vaginal speculum. The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers. The patented technology that is Mia by XytoTest enables laboratories to detect Hr-HPV DNA and allows for risk stratification by detecting biomarkers mRNA E6/E7 from the seven HPV-types proven to be the most crucial for progression to cervical cancer.

"The idea of self-collection using Ma by XytoTest arose from the need to raise awareness of self-care and the need for accessible, routine preventative testing among the sexually active female population. Molecular screening increases sensitivity and specificity, adding clinical value to fight diseases with high morbidity and mortality rates that are ironically preventable, such as cervical cancer," said Mel-Mont Medical's CEO, Frank Melndez.

A recent publication1comparing self-collected to clinician-collected cervical samples to detect HPV infections by a 14-type HPV DNA test and a 7-type HPV mRNA E6/E7 test concludes that Mia by XytoTest equals clinician-collected samples in quality.

"Claiming self-collected specimens accessible for HPV mRNA testing was CE marked to the IVD directive 98/97/EC cleared, making PreTect and its E6/E7 mRNA technology a pioneer for this promising strategy," said Bente Marie Falang, Global Director of In-vitro Division at PreTect, AS.

In addition to providing effective self-sampling options, women who test positive for HPV are, along with their physicians, then prescribed appropriate treatment recommendations specific to each woman's mRNA biomarkers.

Mia by XytoTest and 7-type mRNA E6/E7 afford women new and innovative alternatives in cervical cancer prevention and are now being used across Europe and Mexico. Further, the device permits women in healthcare-deprived countries or with economically-distressed circumstances to access affordable, live-changing technology.

"Integrative multi-disciplinary molecular testsaccurately triaging exfoliated cervical specimens will improve cervical cancer prevention programs while simplifying healthcare procedures in HPV-infected women. Hence, the concept of a "liquid biopsy" (i.e., "molecular" Pap test) highly specific for early identification of cervical precancerous lesions is of critical importance in the years to come,"2 indicated Ana Gradssimo, Ph.D. from Albert Einstein College of Medicine, Bronx, NY a recent publication (2).

About Mel-Mont Medical, Inc.:Mel-Mont Medical, having offices in the United States and Europe, is a boutique medical device and technology company initially focused on products that use mRNA to screen and diagnose, through minimally-invasive means, HPV-caused cancers.

About PreTect, AS:PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

1https://rdcu.be/clGVo 2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904788/

For more information: Bente Marie FalangUstadhagan 8 /N-3490Klokkarstua, NorwayPhone: +47.32.79.88.00Email: [emailprotected]Web: http://www.mel-montmedical.com

SOURCE Mel-Mont Medical, Inc.

mel-montmedical.com

Continue reading here:
Mel-Mont Medical announces the validation of its patented self-sampling technology, Ma by XytoTest, for molecular screening using HPV-DNA and 7-Type...

Posted in Molecular Medicine | Comments Off on Mel-Mont Medical announces the validation of its patented self-sampling technology, Ma by XytoTest, for molecular screening using HPV-DNA and 7-Type…

Kennesaw State graduate blends arts and science, evolves as researcher – News

Posted: August 5, 2021 at 1:59 am

Hope Didier

KENNESAW, Ga. (Jul 30, 2021) Hope Didier forged her own path at Kennesaw State an academic journey that blended divergent passions in dance and the sciences.

The July graduate will earn two bachelors degrees this week in fields not typically paired: dance and molecular and cellular biology. Didier intertwined the two degrees seamlessly, serving as stage manager in multiple dance productions and spearheading cancer cell research that led to scholarly recognition at state and national levels. This fall, she will continue her education at Wake Forest University in a molecular medicine doctoral program.

I would take certain biological principles or ideas and use them as a foundation for a piece I was choreographing or to better educate my peers on what our bodies are actually doing as we move and dance in space, said Didier, who has been dancing since age 3.

As a scientist and dancer, I can appreciate the movement of the often unseen aspects of life under a microscope, in a way that Im not sure many would, and then translate that work in a manner that could be understood by more individuals, no matter their background or expertise.

Didier credits her parents, who teach middle school math and science, for her biology enthusiasm. She added that her parents encouraged creativity and curiosity, and also have a strong interest in music, which likely led to her dance involvement at an early age. Like many of her friends, Didier contemplated a ballet career, having danced with the Atlanta Ballet throughout high school and performed at the Fox Theatre and the Cobb Energy Centre.

Didiers interest in KSU Journey Honors College led her to apply to its Presidents Emerging Global Scholars (PEGS) program, an initiative that challenges Honors students to grow as scholars, leaders and innovators. She was impressed by the faculty who interviewed her for the program and the opportunity to study abroad in both Costa Rica and Italy during her first year.

A friend from the PEGS program introduced her to Jonathan McMurry, a biochemistry professor in the College of Science and Mathematics, since Didier was eager to explore scientific research as an undergraduate.

Hope was so obviously driven, intelligent, and genuinely interested in research, McMurry said. I saw untapped potential in her as a freshman, and thats the type of student researcher every professor wants to encounter.

Didier evolved into an accomplished and disciplined researcher, focusing on using cell-penetrating peptides, or short chains of amino acids, to deliver biomolecular cargo into cervical cancer cells to stop cell growth and catalyze cell death.

She presented aspects of her work at the National Conference on Undergraduate Research twice, and Posters at the Georgia State Capitol in 2020. She won the Top Poster Award at the Birla Carbon Symposium, in which she spent the entire summer conducting research, and received the Anthony Shuker Scientific Award at the Georgia BioInnovation Summit, both in 2018.

Didiers research interests in the healthcare field carried over into volunteering and conducting research at the Emory Winship Cancer Institute and working in the trauma/surgery ICU at Wellstar Health Systems Kennestone Hospital as an operating room surgical technician.

I witnessed firsthand the frontlines of the global pandemic and had the terrifying privilege of holding the hands of critically ill and dying patients, Didier said. It was physically and emotionally challenging, but also made it increasingly clearer to me that I am meant to serve patients and advocate for the very best healthcare practices.

Ultimately, the Peachtree City, Ga. native knew that her trajectory would lean more toward a career in medicine.

Classes like kinesiology and nutrition and learning the way the body moves and works has opened my eyes to how I could meld my two passions, she explained. Im going to keep dancing as part of my life, whether Im teaching on the side or doing small work for studios or companies.

As part of KSU Journey Honors College, Didier completed two Honors theses one in biology on the deterioration and death of cervical cancer cells and the other in dance, focused on a kinesiological approach for understanding the biological phenomenon of programmed cell death.

Didier credits the dance program for expanding her knowledge and techniques, preparing her for any aspect of dance. She learned about the production side of dance from part-time instructor David Tatu, and worked alongside him last spring on a unique production, Moon Dust, a collaboration between the College of the Arts and the College of Computing and Software Engineering.

As an artist and a scientist, I have found that there is this shared zeal for inquiry and constant curiosity, which makes solving problems and creating art so exciting, she said. My two worlds have a lot to learn from one another, and I look forward to future opportunities in which my passions can come together to create something beautiful and share knowledge in an innovative way.

Now Didier is ready to take on the next challenge, pursuing a doctorate in molecular medicine and translational science at Wake Forest University. She will then transition into the physician assistant program in the Wake Forest School of Medicine.

My entire time at KSU has been a massive highlight of my life and always will be, Didier said. The people are what make KSU amazing, and for that I am eternally grateful.

Jolle Walls

Photos by David Caselli

A leader in innovative teaching and learning, Kennesaw State University offers undergraduate, graduate and doctoral degrees to its more than 41,000 students. With 11 colleges on two metro Atlanta campuses, Kennesaw State is a member of the University System of Georgia and the second-largest university in the state. The universitys vibrant campus culture, diverse population, strong global ties and entrepreneurial spirit draw students from throughout the region and from 126 countries across the globe. Kennesaw State is a Carnegie-designated doctoral research institution (R2), placing it among an elite group of only 6 percent of U.S. colleges and universities with an R1 or R2 status. For more information, visit kennesaw.edu.

Read the original:
Kennesaw State graduate blends arts and science, evolves as researcher - News

Posted in Molecular Medicine | Comments Off on Kennesaw State graduate blends arts and science, evolves as researcher – News

Journal Board Members Resign After Controversial Papers – The Intercept – First Look Media

Posted: August 5, 2021 at 1:59 am

Eight members of the editorial board of a scientific journal have resigned after it published a slew of controversial papers that critics fear could be used for DNA profiling and persecution of ethnic minorities in China.

The journal, Molecular Genetics & Genomic Medicine, is the latest to be caught up in controversy involving ethically fraught research. Emails obtained by The Intercept show that the journals editor-in-chief has been slow to respond to queries about the papers, which involve research on Tibetans and Uyghurs, among other ethnic groups, and were first brought to her attention in March. The journal is published by Wiley, a multinational company based in New Jersey that is one of the worlds premier scientific publishers.

Studies involving DNA profiling, facial recognition, and organ transplantation have sparked controversy at other journals, but this is the first time that so many members of a journals editorial board eight of 25 have resigned in response to such issues.

Yves Moreau is seen at the Thermodynamics Instituteat the University of Leuven in Leuven, Belgium, on Feb. 4, 2020.

Photo: Lies Willaert

The papers were flagged by Yves Moreau, a bioinformatician at the University of Leuven in Belgium who over the past few years has waged a tireless campaign to get journals to retract troubling or unethical papers.

Moreaus quest began in 2015, when Kuwait announced plans for compulsory collection of DNA from all citizens, residents, and visitors. He helped spearhead an international campaign against the law and won an early victory when it was overturned the following year. He became convinced that if left unchecked, science and artificial intelligence would be used to further authoritarianism. In technology, we have this nice comfortable geek image, he said. But when you really look at the history of technology, you see that it has been a nexus of power forever for at least 2,000 years. While many geneticists have worked for decades to overturn the idea that race is a scientific concept, Moreausaw that authorities around the worldcould exploit new technologies like readily available DNA testing for political gain.

Moreau later turned his attention to DNA profiling in China, particularly in Xinjiang, where an estimated1 million Uyghurs and other ethnic minorities have been interned in camps or forced into labor. Authorities there have alsocollected DNA samples from residents. Moreau periodically runs an automated search for papers on ethically charged topics. Earlier this year, that search turned up 18 papers at Molecular Genetics & Genomic Medicine.

Some of the papers describe genetic differences between ethnic groups. Police can use such research for DNA profiling, to better match crime suspects with DNA samples from the broader population. Other papers relied on samples that Moreau suspected were taken without proper consent. The Chinese government has been collecting DNA from men of all ethnicities, with the aim of building out genetic information for all 700 million males in China. Chinese police also forcibly collect DNA from certain groups, including migrant workers and political dissidents.

While Molecular Genetics & Genomic Medicine isnt a leading outlet for genetic research, it has an impact factor of 2.183, meaning that its papers are cited and read by other scientists. The Wiley name lends it an imprimatur of respectability.

As its title suggests, the journal was founded to focus on genetics research with medical applications. Many of the editorial board members study how genetics can help doctors treat patients or help scientists cure disease. But in 2019, the journal started publishing papers by authors in China on forensic genetics, a field that involves close collaboration with police. Forensic genetics has long been controversial in the United States. It is even more problematic in China, where DNA collection is part of a sustained effort to persecute ethnic minorities and other groups.

The title of one paper published by the journal is Forensic characteristics and genetic affinity analyses of Xinjiang Mongolian group using a novel six fluorescent dye-labeled typing system including 41-Y-STRs and 3 Y-InDels. Another maps genetic differences between branches of Chinas majority ethnic group, Han Chinese, and other groups, including Tibetans and Hui Muslims. Several of the papers list co-authors or funding from institutions affiliated with Chinese police. One lists a co-author from the Public Security Bureau in Tibet, the police agency in the region.

A graphic published in the journalMolecular Genetics & Genomic Medicinepurports to represent the genetic distance between various ethnic groups, including Uyghur groups.

Credit: onlinelibrary.wiley.com

Hart replied the next day. I am looking into this matter and will respond shortly, she wrote. Moreau sent several follow-up emails. But months passed without an update, he told The Intercept.

On Tuesday, in response to questions from The Intercept, the Wiley public affairs office emailed a statement from Hart. We are actively investigating and driving toward a timely, transparent resolution, Hart said. We take the concerns expressed extremely seriously and regret that delayed communications may have indicated otherwise.

In June, Moreau took the issue to the entire editorial board. In a lengthy email, he listed the suspect papers and explained how police in China use forensic genetics.

Other board members echoed his calls for an investigation. Several said they were not actively involved in the journals work and had no idea that the papers had even been published. The journals editorial board positions are honorary; scientists often sit on multiple boards at once.

In emails obtained by The Intercept, Hart wrote to the board that same day, explaining that she had experienced adeath in her familyand had drafted a message to Moreau that ended up trapped in her outbox. I will send a message soon outlining our decision on how to address this issue, she wrote.

A few weeks later, when she had not provided any further explanation to the board or to Moreau, board members started resigning.

I would have wanted to hear much more quickly from the editorial staff, said Ophir Klein, a pediatric medical geneticist at the University of California San Francisco and one of the board members who quit. The lack of communication made me really concerned, he added.

The lack of communication made me really concerned.

Another board member, Joris Veltman, told The Intercept that he has remained on the board so that he can push for scrutiny of the papers. On July 7, Veltman, who is the dean of the Biosciences Institute at Newcastle University Medical School in the United Kingdom, escalated the issue by emailing Wileys management. The publishers director of research integrity, Chris Graf, responded that Wiley would begin an investigation immediately. Veltman asked why Wiley hadwaited so long.

In a statement, a Wiley spokesperson wrote that the companys Integrity in Publishing Group was overseeing the matter. We have completed the first step of the investigation, which is to assess concerns vis--vis our publishing standards, the statement read. We are now proceeding to connect with the authors and the institutional review boards associated with the papers to clarify the consent procedures for the research undertaken. The spokesperson said that the company could not provide a timeline for the investigation, beyond to say that it would likely continue into September.

Moreau said the focus on consent is too narrow. The larger question, he said, is whether the journal should be publishing research on vulnerable minorities, some of which directly involves the authorities persecuting them. Klein, the board member, said that if the research is determined to be unethical, at a minimum it should be retracted.

Moreau is not holding his breath. He has previously secured retractions from IEEE and Springer Nature, two other major scientific publishers, but Wiley has declined to retract a paper on ethnicity and facial recognition that he and others flagged in 2019. In September 2020, the journal, WIREs Data Mining and Knowledge Discovery, issued an expression of concern. The note focuses only on possible misrepresentation of a data set and figure in the article, not broader ethical issues.

Last month, The Guardian reported that the editor of another Wiley journal, Annals of Human Genetics, resigned in September 2020 after Wileydeclined to publish a letter he co-authored with Moreau and others proposing that his and other journals boycott papers from China. In turning down the letter, Wiley senior managers said that publishing it could cause problems for its China office, he told the paper.

Moreau said he will persist. At this point, you cannot stay silent, he told the Molecular Genetics & Genomic Medicine editorial board in one email. This situation is creating a shameful embarrassment that reflects poorly on all medical genetics journals and on the entire medical genetics community. Public trust in human genetics depends on our communitys ability to transparently abide by its moral duty.

View post:
Journal Board Members Resign After Controversial Papers - The Intercept - First Look Media

Posted in Molecular Medicine | Comments Off on Journal Board Members Resign After Controversial Papers – The Intercept – First Look Media

Theragnostics Strengthens Board of Directors with Key Appointments – PRNewswire

Posted: August 5, 2021 at 1:59 am

LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Dr Dennis Langerhas served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies, and has an extensive pharmaceutical company background. He previously served as CEO of Neose Technologies, Inc.; was President of Dr Reddy's North American business; and was Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a Director of the Whitehead Institute for Biomedical Research, Myriad Genetics, Inc. (NASDAQ: MYGN) and Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX). Dr Langer is a graduate ofColumbia University, and earned an M.D. atGeorgetown University School of Medicineand a J.D. at Harvard Law School.

Professor Ken Herrmannis Chair of the Department of Nuclear Medicine at the Universittsklinikum Essen in Germany. Among his many achievements he is a world leading expert in the clinical development of therapeutic and diagnostic radiopharmaceuticals. He was previously Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles ; he also served as Vice Chair of the Department of Nuclear Medicine at Universittsklinikum Wrzburg. He is currently the Chair of the EANM Oncology & Theragnostics committee and Section Editor of the Journal of Nuclear Medicine.He is on the board of Sofie Biosciences.

Ian Gowrie-Smith, Executive Chairman of Theragnostics, said:"We are very pleased to welcome two high calibre board members to Theragnostics. Dennis has significant business and development acumen, extensive experience and a successful track record in working in the pharmaceutical sector. Ken's extensive knowledge in the clinical development and commercialisation of radiopharmaceuticals is key to the advancement and maturity of Theragnostics. Both will aid us in implementing and enhancing our strategy of bringing novel PARPi diagnostic agents and new targeted therapies to patients."

Greg Mullen, Chief Executive Officer of Theragnostics, added:"I am very pleased to have Dennis and Ken with their expertise and track record, join our board. The appointments come at a pivotal time as we prepare for the next stage of growth and complements the management team's expertise as we advance our programmes into clinical development."

Theragnostics technology platform enables the development of molecular radiotherapy based on a PARPi for imaging and treating cancer. Theragnostics modifies a PARPi drug molecule with a radioactive atom to create a radionuclide PARPi (rPARPi). This can either be used to image PARP in a cancer patient for diagnostic use or the radioactive isotope can be used to deliver a therapeutic dose of radiation into tumour cells, which offers the potential to molecularly target the radiation in order to hit and kill tumour cells whilst avoiding damage to healthy cells and associated side effects.

About Theragnostics

Theragnostics is a private clinical-stage pharmaceutical company developing precision oncology products for diagnostic medical imaging and targeted radionuclide therapy. The Company has completed several proof-of-concept phase I and II clinical trials for several radionuclide diagnostics and targeted therapies. For more information, please visit http://www.theragnostics.com.

SOURCE Theragnostics

theragnostics.com

Go here to read the rest:
Theragnostics Strengthens Board of Directors with Key Appointments - PRNewswire

Posted in Molecular Medicine | Comments Off on Theragnostics Strengthens Board of Directors with Key Appointments – PRNewswire

Putting people at the center of medicine, research, and policy – Environmental Health News

Posted: August 5, 2021 at 1:59 am

I remember the feelings of newness, possibility, and responsibility as I sat with classmates in Harvard's Tosteson Medical Education Center in 2012, each of us staring at a blank sheet of paper.

As one of our first medical school assignments, we were tasked with writing a letter to ourselves that we would open four, five, or in my case, nine years later right before graduation.

What could I tell an older, more experienced, and more knowledgeable version of myself, who would have the titles of Doctor of Medicine (MD) and Doctor of Philosophy (PhD)?

I mustered up some thoughts, jotted them down, placed and sealed the letter in an envelope, and handed it in. After about a week, I forgot all about my letter.

This past March, all graduating medical students received emails telling us we would each receive our letters just in time for Match Day the day when medical students around the country find out where they have been placed for residency training.

Now, as I sit prepared to open this written time capsule, I think about the journey that has brought me to this point. Since writing that letter, I've become even more aware of the privileges that I have received and the responsibility that I am tasked with. People trust me with their lives, and I see many at their most vulnerable. I've worked to build skills at the intersection of research, policy, and medicine because I want to treat illnesses while fostering community health and highlighting current systems that leave certain groups to shoulder the burden of environmental exposures and other ills.

Throughout my training, I've worked to keep hold of what first inspired my journey and continues to guide and inspire my work people.

Author Jamaji Nwanaji-Enwerem on Match Day.

Match Day and the residency application process was demanding. I found myself in an ongoing state of personal reflection.

I reflected on my own immigration story, moving from Nigeria to North Carolina with my parents as an infant. My parents immigrated to the U.S. in the hopes of obtaining an education to better their family, their community, and the world. From an early age, I too adopted the principle of "higher education for community service."

Observing ill family, community members, and friends in Nigeria and the U.S. gave me an early appreciation of global health disparities and inspired my pursuit of medicine. I entered Morehouse College, the nation's only historically Black men's liberal arts college, intending to pursue medicine. However, through the Hopps Scholars Program and other initiatives, I fell in love with scientific research. I came to appreciate that by informing and advancing public health practices and clinical care, research has a boundless ability to help people. Upon graduation, I enrolled at Harvard to become a physician scientist.

Each of my patients in medical school served as a "professor of life" leaving me with unforgettable lessons about how their health status was often entwined with social factors, including the environments in which they lived. It is difficult to manage a young girl's asthma or a young man's depression if you don't consider the air quality in her neighborhood or the safety of his home. I learned to see people, not just their disease.

In my PhD research I studied the relationships of human health with outdoor air pollution. I emphasized working on biomarkers, molecular indicators that can help us better detect harmful environmental exposures. The sooner we can detect harms, the sooner we can intervene. Potentially before individuals become ill.

In my postdoctoral work at UC Berkeley, I added approaches to my study designs to better appreciate the social systems embedded in environmental exposures. Whether we are discussing metal in water or air pollution, these exposures don't simply appear and meet people in isolation. They meet people in the places they live, eat, play, and work. For instance, when someone is exposed to harmful lead levels, it's likely from the water they drink, old paint, or contaminated soil. Thus, studying the harmful effects of lead in these people is incomplete if their water sources, homes, and neighborhoods are also not considered. Understanding this interconnectedness is particularly important when trying to prevent additional harms. Similar to caring for patients beyond their disease, through my science, I work to see the people and communities, not just the data.

I also added a Master's degree in public policy to develop skills in areas like negotiation, stakeholder analysis, and implementation. As the COVID-19 pandemic has reminded us, science does not operate in a silo. Scientific discoveries, including those in public health, need the attention and buy-in of those working in areas like business and government to fully benefit the public.

This may seem like a lot of schooling, but each step focused on being an effective changemaker in the real world. These investments were made with the hope that when faced with real challenges, practice will have made me better even if not perfect and I can confidently answer any call to serve.

Credit: Joel Muniz/Unsplash

Just as the residency interview process was wrapping up, I received invitations to give research talks. I centered one talk on the idea of "being in support with communities."

I called on listeners to think about a time when they were supported by a community. I also called on listeners to think about a time when they were supporting a community. Then, I called on the listeners to hold both of these ideas at oncethis is what is meant by being in support with communities.

My entire personal and professional journey has been about being in support with communities. Relatives, community members, instructors, patients, and so many others sacrificed to make my journey possible. They continue to support me. For instance, if not for the exposure to research, graduate school tours, and other experiences that I received as a Hopps Scholar at Morehouse College, I may not have pursued PhD training. If not for the health disparities I observed in communities in North Carolina and Southeast Nigeria, I may not have pursued medical training. If not for the gaps in the health systems and lack of diversity and inclusivity in research that I have become aware of through my MD/PhD training, I may not have pursued policy training.

This particular presentation also provided me with a real-time opportunity to be supportive of my community. Toward the end of the presentation, I received a question from a Black student that reminded me of the importance of representation in the environmental health space.

Student: "I know for a lot of us who are looking to go into academic careers, sometimes it's hard finding institutions and spaces who are willing to hear our stories and sometimes you can get caught up doing research that maybe you're not necessarily interested in or maybe you're not personally affected by. But you seem to do a really good job of relating your experience to your research. Can you talk a little bit about how you do that?"

In response I said, "When you go back and reflect on things it's like 'oh this fits here and here,' but as you're walking through those steps it's not that straightforward ... I would say, don't get frustrated on the front end. The learning of basic research skills and building up your own acumen helps regardless. Once you build yourself up, there is room for you to pivot and directly pursue things that fit your story or your experiences."

After years of training, and reflection on how I can use it to best serve people most in need, I'm headed to the emergency room.

When most people think about emergency medicine, they think about ambulances, sirens, and gory trauma. However, the emergency room also serves as a safety net for many vulnerable populations (individuals without primary care providers, the uninsured, patients lost to follow-up). Although it is not ideal for an emergency room to serve this purpose, these patients still show up and need help.

Many of these same individuals experience the brunt of health system failures and health disparities worldwide. They bear a disproportionate burden of toxic exposures and other environmental injustices. They are disenfranchised by racism and other forms of systemic oppression in our society. Again, these people exist beyond their diseases and to be truly effective, their "treatments" must be holistic potentially requiring medicine, research, and policy solutions.

For this reason, emergency departments are an ideal place to continue learning, advocating, and serving for someone with my skill set.

On March 19, 2021, I was thrilled and grateful to learn I'd be a resident physician in the Department of Emergency Medicine at Emory.

I also opened my letter from nine years prior. I wondered if I would even recognize myself in it. I did.

"Dear Dr. Jamaji,

Sounds weird huh? No worries, you know what it took for you to get here. First, good job and hopefully too much hasn't changed. The purpose of this letter is to see if you've maintained the same humanity/compassion that you entered HMS with ... it's not all about you and I want to make sure that you never forget that ... by starting your life as a doctor, you have a duty to help everyone. Maintain your strong relationship with God as he has made everything possible. Also, never stop mentoring. Always remember the importance of fostering the future ... Very few make it and are given the opportunities that you have so NEVER FORGET ...

Live, Love, Laugh,

Jamaji August 30, 2012 1:27 PM TMEC Amphitheater"

As I transition to my new role, I take these words, my experiences, and all that I have learned with me.

There is so much work to be done to make the world more equitable. I remain energized and committed to doing my part and working with communities to help actualize this healthier and more equitable future.

Jamaji Nwanaji-Enwerem is an Emergency Medicine Resident Physician at Emory University School of Medicine and an Adjunct Assistant Professor of Environmental Health at Emory Rollins School of Public Health. You can contact him on twitter @JNwanajiEnwerem

Link:
Putting people at the center of medicine, research, and policy - Environmental Health News

Posted in Molecular Medicine | Comments Off on Putting people at the center of medicine, research, and policy – Environmental Health News

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus – PRNewswire

Posted: August 5, 2021 at 1:59 am

The cooperation will be based on the anti-COVID-19 drug R&D project by Westlake Pharma, which aims to develop broad-spectrum small molecule inhibitor drugs for key enzymes of coronavirus and has achieved positive results in the preliminary stage. According to the agreement, the two parties will combine the advantages of Insilico Medicine's AI-powered platforms for drug R&D, and further utilize interdisciplinary molecular design methods such as artificial intelligence, computer simulation and pharmacodynamic to design, synthesize and optimize novel selective small molecule inhibitors to accelerate the advancement of pre-clinical and clinical research on the anti-COVID-19 project.

The epidemic caused by the Novel Coronavirus is still ongoing, which has had a significant impact on human health and economic development and has brought severe challenges to global public health security. The close collaboration between Insilico Medicine and Westlake Pharma aims to strengthen multi-party communication and jointly achieve a scientific and technological breakthrough to bring efficient solutions to the R&D of innovative therapies for the Novel Coronavirus (COVID-19), severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and other coronaviruses.

"AI technology can greatly shorten the duration for new drug R&D. Insilico Medicine has an efficient AI-powered platform for drug R&D, and Westlake Pharma is committed to focusing on major human diseases and developing First-in-Class drugs with independent intellectual property rights. We believe that the cooperation between us will be a strong combination of "AI + drug R&D", which will achieve the goal of "1 + 1 > 2", said Prof. Yu Hongtao, the founder of Westlake Pharma.

"Most of the original innovations in biomedicine came from scientific research institutions. Based on a Westlake University, jointly founded by Prof. Yu Hongtao (Dean of the School of Life Science, Westlake University), Prof. Hu Qi and Prof. Huang Jing, the Westlake Pharma is a biomedical enterprise focusing on original innovations. Insilico Medicine is honored to cooperate with Westlake Pharma. We would like to combine our unique AI platform with Westlake Pharma's characteristic technical methods in cell biology, structural biology and medicinal chemistry to jointly accelerate the development of innovative therapies, and provide solutions for unmet clinical needs, such as Novel coronavirus pneumonia", said Dr. Ren Feng, Chief Scientist Officer and Director of Drug R&D of Insilico Medicine.

About Insilico MedicineInsilico Medicine, an end-to-end artificial intelligence-driven drug discovery companydeveloping artificial intelligence platforms (www.insilico.com/platform/)that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties. It is developing breakthrough solutions for the discovery and development of innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases. Since 2014, Insilico Medicine established strategic collaborations with over 30 pharmaceutical and biotechnology companies and academic research groups in the United States, Europe, China, Japan and other countries and regions, and launched multiple internal R&D pipelines for novel, difficult and previously undruggable targets. It also established a collaboration with Syngenta to develop and apply AI to sustainable agriculture. Since its inception, the company raised over $300 million from the reputable financial, biotechnology, and information technology investors.

About Westlake PharmaRelying on Westlake University, established in September 2020, and headquartered in Yunqi Town (Xihu District, Hangzhou, Zhejiang), the Westlake Pharma, Inc. (Hangzhou) is a talent-led, technology-driven, and innovative-model biomedical enterprise. The founding team was led by Prof. Yu Hongtao, a world-renowned cell biologist and the Dean of the School of Life Sciences of Westlake University, and Prof. Hu Qi and Prof. Huang Jing of the School of Life Sciences of West Lake University. Based on the in-depth understanding of life sciences, combined with the application of interdisciplinary technical methods such as cell biology, structural biology, medicinal chemistry, artificial intelligence, etc., Westlake Pharma exerts strong scientific and technological innovation capabilities, deepens research and development on selected product pipelines, and maintains a leading position in the sub-divisions. With strong support from international CRO/CDMO companies, DEL to PROTAC technology platforms as well as AI data platforms, the enterprise is committed to developing First-in-Class original new drugs with independent intellectual property rights for major human diseases.

Contact: [emailprotected]

SOURCE Insilico Medicine

insilicomedicine.com

See more here:
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus - PRNewswire

Posted in Molecular Medicine | Comments Off on Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus – PRNewswire

Health experts welcome full approval of Pfizer COVID-19 vaccine in coming weeks – The Boston Globe

Posted: August 5, 2021 at 1:59 am

Thats welcome news to public health experts. Several argued that Pfizers two-shot messenger RNA vaccine could have received final approval as early as May before the highly contagious Delta variant became the dominant strain in the United States removing a potential barrier for Americans who say they are wary about receiving a vaccine that has only received emergency use clearance.

I cant believe its taken this long, said Dr. Monica Gandhi, an infectious diseases doctor at the University of California, San Francisco.

Pfizer was the first drug company to receive an emergency use authorization for a coronavirus vaccine from the FDA, on Dec. 11. The New York pharmaceutical giant then filed an application for full approval on May 7.

Two other drug makers, Cambridge-based Moderna and New Brunswick, N.J.-based Johnson & Johnson, followed Pfizer in receiving emergency use authorizations. Moderna filed for final approval of its vaccine on June 1 but is still submitting data. Johnson & Johnson has not yet applied.

Until the COVID-19 pandemic, the FDA had never cleared a new vaccine for emergency use.

Before granting full approval, however, the FDA will have to review much more clinical trial data than the agency did for emergency authorization. Regulators are also expected to consider real-world data on the safety and effectiveness of the vaccine, and will likely conduct inspections of manufacturing plants to ensure stringent quality controls are in place.

Dr. Walter A. Orenstein, a professor of medicine at Emory University and associate director of the Emory Vaccine Center, said approval of COVID-19 vaccines wont sway people who believe in conspiracy theories and dont trust the government, but it will persuade a significant number of hesitant Americans to get vaccinated.

Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, was more skeptical. Hotez has worked on vaccines for neglected tropical diseases afflicting the worlds poorest people and spent years debunking false claims, including that vaccines cause autism. (He wrote a 2018 book called Vaccines Did Not Cause Rachels Autism: My Journey as a Vaccine Scientist, Pediatrician, and Autism Dad.)

Although he welcomes full approval of COVID-19 vaccines, he said a right-wing disinformation empire will roll out a dozen outlandish theories for why people shouldnt get vaccinated, including unfounded allegations that the substances contains microchips, modify a persons DNA, and are instruments of government control.

Its like playing a game of whack-a-mole, Hotez said. Approving the vaccines is the right thing to do, but as an approach to increasing vaccination rates, I dont see it as a game changer.

More than 165 million Americans have been fully vaccinated with one of the three vaccines granted emergency use authorization, according to the Centers for Disease Control and Prevention. But those authorizations are conditional and were given as part of an accelerated and streamlined approval process in a public health emergency. Thats become a talking point for many vaccine opponents who argue that the shots are experimental and potentially unsafe.

A recent poll by the Kaiser Family Foundation, which has been tracking public sentiment during the pandemic, found that three of every 10 unvaccinated people said that they would be more likely to get a shot with a fully approved vaccine. Importantly, of the subset of unvaccinated who described themselves as in wait and see mode, 49 percent told Kaiser that full FDA approval would make it more likely they would finally get an inoculation.

Gandhi, of UCSF, said that although some Americans mistakenly believe the vaccines already have FDA approval, others are aware that they have only been cleared for emergency use. They know that they have to sign a consent form to get a shot, which, she said, would not be the case once the vaccines are fully approved.

That can be a deterrent, she said. Psychologically, it makes it feel like its experimental.

Full approval would do more than remove that impediment, she added. It would give governments and businesses greater legal authority to insist that people be vaccinated if they want to return to work in person or participate in other activities, including eating in restaurants or visiting health clubs.

New York City Mayor Bill de Blasio announced Tuesday that his city will become the first in the country to require proof of at least one dose of a coronavirus vaccine for a variety of activities, to put pressure on people to get vaccinated.

Dr. Eric Topol, a professor of molecular medicine at the Scripps Research Institute in San Diego, expects to see more mandates across the country, especially after drug regulators give vaccines full approval.

Topol, who has served on multiple FDA advisory committees, found it unfathomable how slowly the agency has moved on licensing vaccines compared with the FDAs approval in June of Biogens drug for Alzheimers, a contrast he explored in a recent essay published in The Times.

The FDA, he noted, approved the Cambridge biotechs Alzheimers medication, Aduhelm, through an accelerated process despite limited evidence that it worked in two late-stage trials that enrolled about 3,200 volunteers. In contrast, more than 347 million doses of the three coronavirus vaccines have been administered in the United States, and they have proven overwhelmingly safe and effective. Yet the FDA has yet to act on Pfizers filing for approval.

Theres no bigger health crisis in America than this, obviously, he said. Meanwhile, [regulators] are futzing around with the Alzheimers drug.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com.

See the rest here:
Health experts welcome full approval of Pfizer COVID-19 vaccine in coming weeks - The Boston Globe

Posted in Molecular Medicine | Comments Off on Health experts welcome full approval of Pfizer COVID-19 vaccine in coming weeks – The Boston Globe

Researchers Find Molecular Switch That Regulates Fat Burning in Mice – Newswise

Posted: August 5, 2021 at 1:59 am

Newswise BOSTON Linked to serious health problems including cancer, diabetes and cardiovascular disease, obesity affects more than a third of adults in the United States. Presently, there are few safe and effective nonsurgical therapeutic interventions available to patients with obesity.

Now, a multi-disciplinary team of researchers has demonstrated that a metabolic regulatory molecule called Them1 prevents fat burning in cells by blocking access to their fuel source. Led by microscopy experts at Beth Israel Deaconess Medical Center (BIDMC) and metabolism experts at Weill Cornell Medicine and NewYork-Presbyterian, the study may contribute to the development of a new type of obesity treatment. The teams findings were published June 9 in Nature Communications.

To help explain how the protein Them1 turns off heat production, BIDMCs cell biology and microscopy expert, Susan Hagen, PhD, associate vice-chair for research in the Department of Surgery at BIDMC, and Yue Li, PhD, a postdoctoral researcher in her laboratory, used light and electron microscopy to observe Them1 in action in mouse brown fat cells grown in the laboratory.

Them1 is an interesting molecule, said Hagen. If you inhibit or block its expression, metabolism increases and that reduces body weight.

The experiments showed that when the cells are stimulated to burn fat, a chemical modification causes Them1 molecules to spread out, or diffuse, throughout the cell. This frees the cellular powerhouses called mitochondria to efficiently turn the cells fat stores into energy. But when the stimulation stops, Them1 molecules quickly reorganize into a structure called a biomolecular condensate. Situated between the mitochondria and the fats they use as fuel, the condensed Them1 molecules limit energy production.

It turned out to be so incredibly interesting, said Hagen, who is also director of Microscopy and Histology Core Facilities at BIDMC and associate professor of surgery at Harvard Medical School. We asked other microscopy experts whether they had ever seen anything like the unusual images we found in resting cells. Using very sophisticated electron microscopy techniques, we were able to show for the first time, as far as we know what the bimolecular condensate looks like in electron microscopy.

The study explains a new mechanism that regulates metabolism, said David Cohen, chief of the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medicine. Them1 hacks the energy pipeline and cuts off the fuel supply to the energy-burning mitochondria. Humans also have brown fat and produce more Them1 in cold conditions, so the findings may have exciting implications for the treatment of obesity.

Cohen and Hagen, both members of the Harvard Digestive Diseases Center, have been collaborators since 1983. The current study supported in part by a five-year, multi-PI grant from the National Institutes of Health also included collaborators with expertise in structural biology from Emory University.

This was the most fun I have ever had in science in my life, Hagen added. Including multiple primary investigators with different expertise gives you the power of doing things that you could never do on your own.

Co-authors included Yue Li, Samaksh Goyal, Lay-Hong Ang, and Mahnoor Baqai of BIDMC; Norihiro Imai, Hayley T. Nichols, Tibor I. Krisko of Weill Cornell; Blaine R. Roberts, Matthew C. Tillman, Anne M. Roberts, and Eric A. Ortlund of Emory University.

This work was supported by the National Institutes of Health (R01 DK 103046, R01 DK0488730 and NIHT32DK007533), the Harvard Digestive Disease Center (P30 DK034854) and the National Institutes of Health shared-instrumentation grant program for the High Pressure Freezer (S10 OD019988-01), the Pinnacle Research Award from the AAASLD Foundation, Weill Cornell Department of Medicine Pre-Career Award, and an American Heart Association Postdoctoral Fellowship, and a Research Science Institute/Center for Excellence in Education Summer Research Fellowship.

The authors declare no competing interests.

About Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center is a patient care, teaching, and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. For more information, visitwww.bidmc.org.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

Visit link:
Researchers Find Molecular Switch That Regulates Fat Burning in Mice - Newswise

Posted in Molecular Medicine | Comments Off on Researchers Find Molecular Switch That Regulates Fat Burning in Mice – Newswise

OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting – GlobeNewswire

Posted: August 5, 2021 at 1:59 am

ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen or the Company), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that it has determined to withdraw from stockholder consideration Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 26, 2021, relating to an increase in the number of shares of capital stock authorized for issuance under the Companys Amended and Restated Certificate of Incorporation. In light of the withdrawal of such proposal, the Company has determined to cancel the reconvening of the adjourned portion of its Annual Meeting of Stockholders for the consideration of Proposal 2, which was previously adjourned solely with respect to Proposal 2 to 10:00 a.m. Eastern Time on August 5, 2021. All other proposals in the Companys Definitive Proxy Statement were previously submitted to a vote of stockholders at the Annual Meeting on June 9, 2021, at which all such proposals were approved. The Company plans to continue evaluating alternatives for financing the future development and growth of the Company.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGens Annual Meeting. These statements and other statements regarding OpGens Unyvero products, their commercialization and launch, future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:Oliver SchachtPresident and CEOInvestorRelations@opgen.com

OpGen Press Contact:Matthew BretziusFischTank Marketing and PR matt@fischtankpr.com

OpGen Investor Contact:Max ColbertEdison Groupmcolbert@edisongroup.com

Visit link:
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting - GlobeNewswire

Posted in Molecular Medicine | Comments Off on OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting – GlobeNewswire

Page 686«..1020..685686687688..700710..»